PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE persons are required to respond to a collection of information unless it contains a valid OMB control number

Under the Paperwork Reduction Act of 199 persons are requ

Substitute for Form 1449/PTO	Complete if Known			
	Application Number	10/790,544		
INFORMATION DISCLOSURE	Filing Date	March 1, 2004		
STATEMENT BY APPLICANT	First Named Inventor	Miroslav Colic		
(Use as many sheets as necessary)	Art Unit	1646		
(est as many should as housestay)	Examiner Name	Xiaozhen Xie		
Sheet 1 of 2	Attorney Docket Number	4904-4DIV		

			U.S. PAT	ENT DOCUMENTS	
Examiner Cite No. 1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant	
	No.	Number-Kind-Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear
		US-			
		US-			
·		US-			
		US-			
	·	US-			
		US-		*	
		US-			
		US-			
-		US-			
		US-			
		US-			
		US-			

			FOREIGN P	ATENT DOCUMENTS		
Examiner Initials*	Cite No. 1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or	T _e
		Country Code ³ · Number ⁴ · Kind-Code ^{5 (if known}			Relevant Figures Appear	
			,			

Examiner Signature	Date Considered	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute fo	or Form 1449/PTC)		Ca	omplete if Known	
				Application Number	10/790,544	
INEO	DMATIO	N DI	CCI OCUDI	Filing Date	March 1, 2004	
	INFORMATION DISCLOSURE			First Named Inventor	Miroslav Colic	
STATEMENT BY APPLICANT (Use as many sheets as necessary)		Art Unit	1646			
	(Ose as many s	meets as i	necessary)	Examiner Name	Xiaozhen Xie	
Sheet	2	of	2	Attorney Docket Number	4904-4DIV	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Katic, M., et al., A Clinoptilolite Effect on Cell Media and the Consequent Effects on Tumor Cells in vitro, <i>Frontiers in Bioscience</i> 11, p. 1722-1732	
		(2006).	
		Žarković, N., et al., Anticancer and Antioxidative Effects of Micronized Zeolite Clinoptilolite, <i>Anticancer Res.</i> 2003 Mar-Apr; 23(2B): 1589-95.	
		Martin-Kleiner, I., et al., The Effect of the Zeolite Clinoptilolite on Serum Chemistry and Hematopoiesis in Mice, <i>Food and Chemical Toxicology</i> 39 (2001) p. 717-727.	
		Pavelić, K., et al., Natural Zeolite Clinoptilolite: New Adjuvant in Anticancer Therapy, <i>J. Mol. Med.</i> (2001) 78:708-720.	
		Pavelić, K., et al., Immunostimulatory Effect of Natural Clinoptilolite as a Possible Mechanism of its Antimetastatic Ability, <i>J. Cancer Res. Clin. Oncol.</i> (2002) 128:37-44.	

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.